NNVC
NanoViricides Inc.
Latest price
As of Oct 26, 2026, 6:34 PM EDT · Market data by Massive
Market cap
$35.8M
Volume
220.9K
Previous close
$1.40
Day range
$1.32 – $1.40
Listed
Jul 5, 2005
Coverage
17 articles
Price performance
Recent trading
Newsroom
Latest NNVC coverage
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
NanoViricides, Inc. (NYSE Amer.: NNVC) reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission (SEC) on Friday, October 13, 2023.
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
NanoViricides, Inc. (NYSE American: NNVC) a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s broad-spectrum antiviral drug, is progressing successfully.
Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
NanoViricides, Inc. (NYSE American: NNVC),
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides – NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
SHELTON, CONNECTICUT – July 6, 2023 – NanoViricides, Inc. (NYSE American: NNVC) reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.
NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
NanoViricides, Inc. (NYSE Amer.: NNVC) a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India (“Karveer”).
NanoViricides Has Filed its Quarterly Report – Company has Begun Production of Coronavirus Drug for Clinical Trials
Wednesday, February 15, 2023 — NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending December 31, 2022 with the Securities and Exchange Commission (SEC) on Tuesday, February 14, 2023.
NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy
SHELTON, CONNECTICUT — August 9, 2022 — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, provides further details on its rapid drug development strategy for Monkeypox virus. The Company believes its Monkeypox drug development program
NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
SHELTON, CONNECTICUT – May 16, 2022 — NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform reports that it has begun drug development to combat recent cases of severe pediatric hepatitis. Specifically, the Company has initiated a prog
NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
Shelton, Connecticut — (November 15, 2021) – NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit no
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
Shelton, Connecticut — (October 11, 2021) – NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology,announced today that its Pan-Coronavirus COVID-19 Drug CandidateNV-CoV-2 was found to be effective against SARS-CoV-2 in a standard cel
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug
Shelton, Connecticut — September 22, 2021 — NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate NV-CoV-2 thereby re
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development
Shelton, Connecticut – September 14, 2019 — NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has completed the process of licensing the human Coronavirus field for drug development and commercialization from TheraCour Pharma, Inc. (“TheraCour”). The Company executed
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application
Shelton, Connecticut — March 2, 2021 — NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicine technology platform, reported today on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is pre
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 – Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND
SHELTON, CONNECTICUT – February 16, 2021 — NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its second quarter of financial year 2021 with the Securities and Exchange Commission.
Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.’s President, Dr. Anil Diwan
Shelton, CT – January 27, 2021 — NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective broad-spectrum antiviral therapies based on a novel nanomedicines platform, today discusses the current developments in the COVID-19 pandemic and the Company’s exciting accomplishments related to it. “
Small Caps Daily Features NanoViricides' Rapid Advancement to Clinical Trials for its COVID-19 Therapy
[ad_1] New York, NY – (NewMediaWire) – November 18, 2020 – NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, was the subject of a recent article on leading financial news website and publisher, Small Caps Daily. NanoVi
NanoViricides: Drug Candidates Show Fantastic Results In Animal Model
In our earlier pieces, we have provided an in-depth coverage of the promising biopharma smallcap NanoViricides Inc. (NYSE American: NNVC) and its huge potential within the anti-viral medications space. The company has rapidly advancement with respect to the drug development process of its COVID-19 drug and a big role was played by CEO Dr. Anil ...